SYDNEY (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh ...
Moderna Inc. on Tuesday reported "positive interim results" from a late-stage trial of what it calls the "next-generation ...
ZURICH (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few ...
HONG KONG/ SYDNEY--Drugmaker Moderna's CEO set off fresh alarm bells in financial markets on Tuesday after he warned that COVID-19 vaccines were unlikely to be as effective against the Omicron ...
In the trial, mRNA-1283 elicited a higher immune response against the SARS-CoV-2 virus, compared to mRNA-1273.222.
Moderna said its Covid vaccine would likely experience a 'material drop' in efficacy against Omicron, while Regeneron ... with London's Financial Times, CEO Stephane Bancel said the existing ...
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life ...
Moderna shares rose Wednesday after it said that it had received up to $750 million from Blackstone Life Sciences to advance its flu program.
Moderna is focusing on advancing its mRNA vaccine pipeline for other viruses following a decline in COVID-19 product sales.
Moderna CEO Stéphane Bancel explains how technology ... final approval to updated COVID-19 vaccines targeting the dominant omicron variant on Thursday. According to the White House's COVID ...
Moderna CEO Stéphane Bancel anticipated that “given the need for a COVID-19 vaccine in infants and young children, we are working with the US FDA and regulators around the world to send these ...